Ensemble and Boehringer Ingelheim to discover macrocycle drug candidates

Ensemble will use its innovative drug discovery platforms to discover and advance drug candidates against Boehringer Ingelheim's drug targets

Ensemble Therapeutics has announced a new research collaboration with Boehringer Ingelheim.

The companies will use Ensemble's innovative platform to identify small molecule drug candidates called macrocycles for several of Boehringer Ingelheim's high-value pharmaceutical targets.

Ensemble's Ensemblin collection of approximately five million macrocycles will be used, with Boehringer Ingelheim having the exclusive right to develop and market any substances arising from the collaboration.

In return, Ensemble will receive upfront payments and research funding, in addition to a possible $186 million in milestone payments and royalties on future product sales.

Dr Michael Taylor, chief executive officer of Ensemble Therapeutics, said that the collaboration builds on Ensemble's strategy to partner with leading pharmaceutical companies "and further validates the wide-ranging potential of our Ensemblin drug discovery platforms while providing Ensemble with additional funding to advance our own internal pipeline".